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The clinical applicability of direct cell fate conversion
depends on obtaining tissue from patients that is
easy to harvest, store, and manipulate for reprog-
ramming. Here, we generate induced neural progen-
itor cells (iNPCs) from neonatal and adult peripheral
blood using single-factor OCT4 reprogramming. Un-
like fibroblasts that share molecular hallmarks of
neural crest, OCT4 reprogramming of blood was
facilitated by SMAD+GSK-3 inhibition to overcome
restrictions on neural fate conversion. Blood-derived
(BD) iNPCs differentiate in vivo and respond to
guided differentiation in vitro, producing glia (astro-
cytes and oligodendrocytes) and multiple neuronal
subtypes, including dopaminergic (CNS related)
and nociceptive neurons (peripheral nervous system
[PNS]). Furthermore, nociceptive neurons pheno-
copy chemotherapy-induced neurotoxicity in a sys-
tem suitable for high-throughput drug screening.
Our findings provide an easily accessible approach
for generating human NPCs that harbor extensive
developmental potential, enabling the study of clini-
cally relevant neural diseases directly from patient
cohorts.
INTRODUCTION
The reprogramming of adult cells into alternative tissues holds
promise for regenerative medicine and drug discovery, espe-
cially for human cell types that are difficult to procure such
as neural tissue (Sancho-Martinez et al., 2012). However, sig-
nificant limitations remain using current technology as it re-
lates to human sources; thus, novel approaches that allow
generation of large numbers of renewable neural cells from
easily accessible tissues derived from donors are required.
Complete cellular reprogramming to the pluripotent state has
gone some way to realize this promise (Takahashi and Yama-Cnaka, 2006). However, although transformative, this advance
is limited by costly and time-consuming methods over several
months to first derive skin fibroblasts and then generate and
characterize resulting iPSCs (Stacey et al., 2013). Further-
more, resulting iPSCs acquire inefficiencies in lineage-specific
differentiation from pluripotent state that limits reproducible
production of specific mature cell types (Lee et al., 2014).
Similarly, the use of hiPSCs in cell replacement therapy
continues to precipitate barriers and concerns that require
laborious measures to assure resulting cells are free from
tumor-forming pluripotent cells has yet to be resolved (Cun-
ningham et al., 2012).
More recent studies have established a paradigm whereby
forced expression of lineage-specific factors allows direct
reprogramming into differentiated somatic cells, including
cardiomyocytes, hepatocyte-like cells, blood, and neurons
without iPSC formation (Efe et al., 2011; Pang et al., 2011;
Szabo et al., 2010). However, direct cell fate reprogramming
of human cells is accompanied by other limitations and
remains inefficient, requiring multiple transcription factors
to be ectopically expressed in every cell, and is largely
based on difficult to obtain human skin biopsies that are
not available from historical clinical studies. Alternatively,
blood cells can be readily obtained from patients, require
no culture derivation prior to reprogramming, and have
been stored and banked (Broxmeyer, 2010) from large
cohort patient trials in the past such as those suffering
from neurological disorders (http://brainbank.ucla.edu and
https://www.clsa-elcv.ca/). Here, we applied our unique
OCT4-induced plasticity reprogramming approach (Mitchell
et al., 2014a) in combination with previously identified
neural potentiating small molecules (Chambers et al., 2009;
Li et al., 2011) to directly convert human blood progenitors
derived from both cord blood and adult sources to neural
progenitor cells (NPCs). We demonstrate that these human
blood-derived (BD)-NPCs are capable of in vivo differentia-
tion and survival as well as tripotent neural differentiation
in vitro that includes neuronal differentiation toward clini-
cally relevant CNS and peripheral nervous system (PNS)
subtypes.ell Reports 11, 1367–1376, June 9, 2015 ª2015 The Authors 1367
RESULTS
Generation of Induced Neural Progenitor Cells from
Neonatal and Adult Blood Cells Using OCT4 and SMAD+
GSK-3 Inhibition
In an effort to make use of readily accessible hematopoietic cells
as a starting material to generate neural derivatives, we em-
ployed OCT4-based reprogramming (Mitchell et al., 2014a,
2014b) to both cord blood and adult peripheral blood progenitors
(Figure S1A). Human blood cells from both sources were nega-
tive for pluripotent markers (SSEA3, TRA1-60), early neural
markers (Nestin, PAX6) as well as neural crest (NC) markers
(p75, CD57) (Figure S1B), thereby excluding the presence of
contaminating cells with pluripotent or NPC features within the
starting blood samples. Transduction with OCT4 alone has pre-
viously been shown to induce human skin fibroblast conversion
to tripotent neural progenitors (Mitchell et al., 2014a), despite re-
ports suggesting the requirement for a chemically diverse cock-
tail of inhibitors in addition to OCT4 (Zhu et al., 2014). However,
transduction of human blood with OCT4 alone failed to induce
production of inducedNPCs (iNPCs) (Figures 1A–1C). As both in-
hibition of SMAD and glycogen synthase kinase-3 (GSK3)
signaling have been independently reported to efficiently neural-
ize hPSCs (Chambers et al., 2009), we examined whether dual
inhibition with SMAD and GSK-3 chemical inhibitors could facil-
itate iNPC generation from blood coupled with OCT4-induced
plasticity (Figure 1A). When human blood progenitors obtained
from neonatal cord blood or adult peripheral blood expressing
OCT4 were transferred to SMAD+GSK-3 inhibition conditions
(SB431542, LDN-193189, Noggin, CHIR99021), iNPC-like clus-
ters appeared within as little as 8–10 days and showed the
expression of the neural stem cell marker, Nestin (Figures 1B
and S1C). The addition of these same molecules to human fibro-
blasts had no effect on NPC generation (Mitchell et al., 2014a,
2014b) (data not shown). As SOX2 has also been implicated in
direct-fate reprogramming toward the neural lineage (Ring
et al., 2012), we tested whether SOX2 transduction alone or in
combination with OCT4 enhanced iNPC-like cluster formation.
We found no detectable iNPC-like clusters upon expression of
SOX2 alone, as well as reduced iNPC formation when used in
combination with OCT4 (Figure 1C). The use of OCT4 expression
combinedwith chemical inhibitors was a highly efficient process,
and up to 12 putative iNPC-like colonies could be generated
from as few as 50,000 (50K) human blood progenitors (Fig-
ure 1C). OCT4-dependent generation of human iNPC colonies
could not be established from more mature blood cells devoid
of CD34 expression (CD34) and was restricted to the hemato-
poietic progenitor-containing compartment (Figure 1D). Further-
more, individual iNPC-like colonies demonstrated robust sur-
vival that allowed subsequent collection and re-culturing to
promote cell proliferation and expansion into primary neuro-
spheres using suspension culture (Ring et al., 2012) conditions
known to support human NPCs (Figure 1E). The absence of
pluripotent markers (TRA1-60 and SSEA3) demonstrated that
OCT4-induced iNPCs were not products of intermediate plurip-
otent states (Figure S1D), which was further supported by the
failure to give rise to teratomas when transplanted into immuno-
deficient mice (Figure S1E). The complete absence of a pluripo-1368 Cell Reports 11, 1367–1376, June 9, 2015 ª2015 The Authorstent cell from human blood derived OCT4-induced iNPC also
removes safety concerns regarding potential future use of BD-
iNPCs. BD-iNPCs derived from either neonatal cord blood or
adult peripheral blood consistently expressed neural stem cell-
associated markers, including PAX6, NESTIN, SOX2, and
CD133 similar to control human NPCs (Figures 1F, 1G, S1F,
and S1G). Moreover, cultured BD-iNPCs contained ki67 ex-
pressing proliferative cells (Figure S1F) that enabled serial
passaging without the loss of NPC marker expression, neural
transcriptional programs, or genomic integrity (Figures S1H–
S1J, S2A, and S2B). As a testament to their robust practical
utility, with an average of as few as 12 iNPC colonies consistently
generated from 50K human blood progenitors, we have deter-
mined that we can generate as many as 100-million progenitor
cells over ten passages (Figure 1H) using this direct-conversion
approach from human blood samples.
SMAD+GSK-3 Inhibition Facilitates NPC Generation
from Human Blood
In order to gain a better understanding for the requirement of
dual SMAD+GSK-3 inhibition during OCT4-mediated conver-
sion of human blood cells to iNPCs, we assembled molecular
profiles of blood cells expressing OCT4 that were either treated
or not treated with inhibitors and compared them with profiles
of recently described Fibs-iNPCOCT4 that were derived in the
same fashion. To evaluate the molecular profiles, we performed
hierarchal cluster analysis of global gene expression profiles
and included SOX2 expressing primary neural stem/progenitor
cells isolated from human brain tissue as a base of reference
(Figure 2A). As expected, Fib-iNPCs were highly related to pri-
mary human NPCs regardless of inhibitor addition (Mitchell
et al., 2014b), whereas BD-iNPCs required SMAD+GSK-3
inhibition in order to cluster together with primary NPCs (Fig-
ure 2A). Investigation of differential gene regulation between ±
inhibitor-treated fibroblasts and blood cells during generation
of NPCs displayed minimal changes in fibroblast transcriptome
compared with blood cells, suggesting a unique role for
SMAD+GSK-3 inhibition during blood based OCT4 reprogram-
ming (Figure 2B). In order to classify the gene programs that
were specifically regulated in blood cells undergoing OCT4
iNPC reprogramming, we performed gene set enrichment anal-
ysis on blood cells ± inhibitor treatment during derivation of
NPCs. The addition of SMAD+GSK-3 inhibition resulted in the
enrichment of multiple neural-related gene sets that were
otherwise not activated in the presence of OCT4 expression
alone (Figure 2C). Furthermore, filtering of both upregulated
and downregulated genes using the Tissue Expression analysis
tool on DAVID Bioinformatics Resource revealed enrichment of
downregulated genes within hematopoietic programs and up-
regulated genes within neural programs (Figure S2). In order
to validate the trends from our molecular profiling studies, we
performed candidate quantitative PCR (qPCR) on BD-iNPCs
for potent hematopoietic and neural progenitor regulatory
genes, which confirmed a successful molecular switch from
blood to neural progenitors (Figure 2D). These detailed ana-
lyses indicate the processes involved in conversion of human
skin fibroblasts to NPCs versus blood derived NPCs are also
molecularly distinct and reveal a complete conversion of human
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Figure 1. Generation of iNPC from Neonatal and Adult Blood Cells
(A) Schematic for deriving iNPCs from lineage-depleted CD34+CD45+ blood.
(B) Phase-contrast images of iNPCs. Scale bar represents 300 mm.
(C) iNPC colony numeration. Scale bar represents SD.
(D) iNPC colony numeration from CD34+ or CD34 cells. Scale bar represents SD.
(E) Phase-contrast image of iNPC spheres. Scale bar represent 300 mm.
(F) Immunofluorescence of iNPCs for PAX6, Nestin, and SOX2. Scale bar represents 100 mm.
(G) FACS for PAX6 and NESTIN, from iNPCs (n = 4).
(H) Predicted iNPCs from 50K human blood progenitors. Scale bar represents SD.blood progenitors to NPC fate that is not limited to phenotypic
alternations alone.
BD-iNPCs Expand and Functionally Respond to In Vivo
and Directed In Vitro Differentiation Cues
Having established the role for SMAD+GSK-3 inhibition during
the initial generation of BD-iNPCs from human blood progeni-
tors, we next examined the direct effects on proliferative expan-
sion and developmental potential of the resulting BD-iNPCs.
SMAD+GSK-3 inhibition resulted in enhanced proliferation ofCBD-iNPCs compared with inhibitor-withdrawn cultures (Fig-
ure S3A). However, enhanced proliferation came at the expense
of differentiation, as BD-iNPCs maintained in the presence
of SMAD+GSK-3 that were transferred to culture conditions
conducive for neuronal differentiation (Figure S3B), displayed
continued PAX6 expression but failed to upregulate Tuj1
compared with BD-iNPCs where inhibitors were withdrawn
(Figures S3C and S3D). Despite a clear indication that inhibitor
treatment imposed differentiation block, this phenomena was
rapidly reversed within one round of passaging in the absenceell Reports 11, 1367–1376, June 9, 2015 ª2015 The Authors 1369
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Figure 2. Molecular Profiling of OCT4 BD-iNPC Generation
(A) Hierarchal cluster analysis on global gene expression of Fib-iNPC and BD-iNPC ± inhibitors with primary human NPC.
(B) Number of genes changing in response to inhibitors in Fib-iNPC versus hBD-iNPCOCT4 (false discovery rate [FDR] p% 0.05, fold changeR1.5).
(C) GSEA on iNPC ± inhibitors.
(D) Expression of hematopoietic or neural specific genes in BD-iNPCs and control NPCs derived from hPSCs. Scale bar represents SD.of inhibitors, indicative of successful maintenance of differentia-
tion potential throughout proliferative cycles (Figures S3E and
S3F). Interestingly, quantified levels of PAX6 in long-term cul-1370 Cell Reports 11, 1367–1376, June 9, 2015 ª2015 The Authorstures revealed that the expression of the NPCmarker was higher
in the presence of SMAD+GSK-3 inhibitors, although the fre-
quencies of positive cells were comparable (Figures S3G and
S3H). These results reveal that modulation of SMAD+GSK-3
signaling plays an important role in the regulation of proliferation
and differentiation potential of BD-iNPCs.
We next set out to evaluate the developmental potential of
OCT4 induced BD-iNPCs by assessing their ability to function-
ally differentiate in vivo toward the three main neural lineages.
BD-iNPCswere transducedwith aGFP expressing lentiviral vec-
tor and then injected into the brains of p2–p4 mouse pups and
allowed to engraft for 3 weeks (Zhu et al., 2014). Analysis of
GFP signal from sectioned brain tissue as a surrogate of human
engraftment revealed multiple sites containing intact human
cells (Figure 3A). Investigation for differentiated BD-iNPC prog-
eny revealed populations of GFP-positive cells that co-ex-
pressed both TUJ1 and MAP2 with clear neuronal morphology
(Figure 3B). Moreover, we identified GFP-positive human cells
that also co-expressed glial fibrillary acidic protein (GFAP),
consistent with the presence of astrocytes (Figure 3B). Despite
confirming in vivo differentiation potential toward both neurons
and astrocytes, we did not find evidence of in vivo differentiation
toward oligodendrocytes, a finding not unlike that of other hu-
man iNPC studies that have relied on murine xenograft assays
(Zhu et al., 2014).
Although in vivo xenograft studies are considered to be the
gold standard for many assays of human biology that can other-
wise not be measured, in vitro differentiation allows for the
directed production of specific cell types that will likely be
useful in near term personalized medicine applications of drug
screening/testing rather than cellular transplantation. Despite
limited detection of oligodendrocytes in our in vivo tests,
BD-iNPCs possessed astrocyte and oligodendrocyte differenti-
ation potential in vitro, as evidenced by GFAP and O4 expres-
sion, respectively, with characteristic morphology similar to
differentiated cells from human PSCs (Figures 3C, 3D, and
S3I). Furthermore, culture conditions for the specification for
neuronal development resulted in mature neurons expressing
canonical markers TUJ1 and MAP2 (Figures 3E and S3J), with
the majority expressing high levels of glutamate, consistent
with excitatory glutamatergic neurons. Importantly, prior to dif-
ferentiation BD-iNPCs express OCT4 transgene at observable
levels, however, similar to previous reports (Mitchell et al.,
2014b), OCT4 expression is silenced upon complete differentia-
tion toward mature functional cells types (Figure S3K). Using
specific conditions for GABAergic neurons, we successfully
generated GABA-positive inhibitory neurons (Figure 3E), sug-
gesting BD-iNPCs harbored broad neuronal developmental po-
tential. Moreover, BD-iNPC derived neurons also exhibited a
punctate pattern of synapsin expression, suggesting the devel-
opment of synapses (Figure 3F), which was confirmed using
electrophysiological analysis (Figures 3G and 3I). Specifically,
upon positive current injection, spontaneous repetitive action
potential firing was induced (Figure 3G), and voltage-dependent
transient Na+ and sustained K+ currents were detected (Fig-
ure S3L). Application of tetrodotoxin (TTX) blocked rapidly acti-
vating and inactivating inward currents, further demonstrating
that the differentiated neurons expressed voltage-activated so-
dium channels associated with primary neurons (Figure 3I).
Thus, neurons derived from iNPCs appear to exhibit the func-
tional membrane properties and activities of mature neurons.CHaving observed robust functional neuronal differentiation activ-
ity, we investigated whether BD-iNPCs neuronal differentiation
capacity could be expanded into more specialized neurons,
such as dopaminergic (DA) neurons, in response to specific in-
structions. We found that treatment with Sonic Hedgehog
(SHH) and FGF8b (Li et al., 2011) further differentiated BD-iNPCs
into neurons expressing tyrosine hydrolase (TH), the rate-limiting
enzyme in the synthesis of DA (Figure 3J). These neurons also
expressed the nuclear receptor NURR1 (also known as
NR4A2), a key regulator of the DA system (Figure 3J). Moreover,
the detection of secreted DA in culture medium further sup-
ported the presence of functional DA neurons in vitro (Figure 3K).
Taken together, these results confirm that BD-iNPCs are
capable of robust expansion without sacrificing their broad
developmental potential and thereby exhibit the most critical
features of bona fide human neural progenitors.
BD-iNPC Generate Functional Nociceptors that Model
Chemotherapy-Induced Neuropathy
Based on the broad neuronal developmental potential of BD-
iNPCs, we further analyzed the transcriptome of BD-iNPCs.
These analyses revealed an enrichment of neural crest cell-
related gene activity compared with that found in blood progen-
itors (Figure 2C). Recent work has demonstrated the conversion
of human fibroblasts to both putative neural crest (Kim et al.,
2014), as well as sensory neurons (neural crest-derived periph-
eral neurons) using typical lineage specifying transcription factor
reprogramming strategies (Blanchard et al., 2015; Wainger et al.,
2015). Despite a lack of neural crest or sensory neuron functional
activity in starting populations of fibroblasts, these human fibro-
blasts were found to be enriched for neural crest-related genes
compared with that of human blood cells, suggesting a tran-
scriptionally primed state of neural potential for conversion to-
ward the neural lineage within skin fibroblast cultures not seen
in blood progenitors (Figure 3L). Therefore, in contrast to skin fi-
broblasts, BD-iNPC conversion involves de novo acquisition of
neural crest-related gene expression (Figure 3M). Based on
this observation, we hypothesized that their developmental po-
tential may extend to the peripheral nervous system derivatives,
such as sensory neurons.
Recent work has demonstrated that combined small-mole-
cule inhibition (SU5402, DAPT, and CHIR99021) converts human
pluripotent cells into sensory neurons (nociceptors) (Chambers
et al., 2012). Based on previous reports (Chambers et al.,
2012; Guo et al., 2013), wemademodifications to this procedure
(Figure S4A) and tested whether these small-molecule inhibitors
could induce generation of nociceptive sensory neurons from
directly converted human neonatal and adult BD-iNPCs. We
found that the canonical sensory neuronal markers ISL1 and
BRN3A were expressed within differentiated neuron prepara-
tions from cord blood and adult peripheral blood BD-iNPCs, in
a similar fashion as human embryonic stem cell (hESC)-derived
cells shown previously (Figure 4A). In addition, sensory culture-
derived neurons expressed glutamate, consistent with an excit-
atory glutamatergic neuronal phenotype (Figure S4B), and
demonstrated transcript-level expression of sensory neuron-
related genes such as NTRK1, 2, and 3 receptors, neurofilamin
heavy chain peptide (NEFH), and calcitonin-related peptideell Reports 11, 1367–1376, June 9, 2015 ª2015 The Authors 1371
Figure 3. In Vivo and In Vitro Differentiation Potential of BD-iNPCs
(A) Montage of individual images from sectioned brain tissue 3 weeks after injection of BD-iNPCs expressing GFP (‘‘R’’ - zoomed images have been manually
aligned for visual continuity).
(B) In vivo differentiation of BD-iNPCs into neurons (expression of Tuj1, MAP2, and NeuN) and astrocytes (expression of GFAP).
(legend continued on next page)
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alpha (CALCA) (Figure S4C). These results confirmed that upon
treatment with appropriate culture conditions, BD-iNPCs were
capable of generating putative sensory neurons; supportive of
our idea that BD-iNPC developmental potential extends to
PNS-related progeny.
Given strong clinical interest for furthering our understanding
of neurological pain and neuropathy conditions (Bennett and
Woods, 2014; NCI, 2010), combined with the notion that noci-
ceptive neurons (NTRK1 expressing) can be functionally as-
sayed (Blanchard et al., 2015; Wainger et al., 2015), we decided
to focus our efforts on nociceptive (NTRK1) neuron generation
from BD-iNPCs for further characterization and optimization for
use. Analysis of NTRK1 expression at the protein level revealed
approximately 50%of differentiated cell positivity of putative no-
ciceptors (Figure 4B). Over 14 days, analysis of ISL1, BRN3A,
and NTRK1 expression indicated that putative nociceptive sen-
sory neurons could be sustained and continually generated from
differentiating BD-iNPCs over time (Figure 4C). Induced neurons
were often organized into ganglia-like structures in long-term
culture and expressed Substance P (TAC1), indicating the pres-
ence of peptidergic nociceptors (Figure 4D). Moreover, the
expression of nociceptor-specific channels and receptors was
upregulated during sensory neural induction (Figure 4E). Expres-
sion of the purinergic receptor, P2RX3, considered a unique
phenotype of human sensory neurons (Jarvis et al., 2002), was
confirmed by immunofluorescence analyses (Figure 4F).
Functionally, human cord blood and adult BD-iNPC-differenti-
ated neurons were evaluated using calcium flux in response to
a,b-methylene-ATP (a,b-meATP), a selective agonist of P2X3
(Figures 4G and 4H) (Jarvis et al., 2002). Although neurons at
day 7 post-induction showed expression of putative sensory
neuron markers (Figure 4C), only a minimal response to a,b-me-
thylene-ATP was detectable, whereas continued culture to day
14 allowed a robust response to manifest (Figures 4I, 4J, and
S4D). This indicates that the development of phenotype alone
does not suggest functional capacity in terms of ligand respon-
siveness—an important caution in pragmatic use of converted
human neuronal cell types. Furthermore, both the TRPV1 vanil-
loid receptor agonist capsaicin and P2X3 agonist a,b-meATP
could evoke calcium transients in BD-iNPC derived neurons
(Caterina et al., 1997), demonstrating functional activity of
nociceptive sensory neurons (Figures 4I, 4J, and S4D). Im-
portantly, A-317491, a selective P2X3 inhibitor, significantly
decreased this response (Figure 4K), providing evidence that
the a,b-meATP mode of action was indeed through activation
of P2X3 receptors (Figure 4K). Our findings demonstrate the
differentiation potential of BD-iNPCs into nociceptive sensory(C–E) In vitro differentiation of BD-iNPCs in to GFAP-positive astrocytes (C) an
glutamatergic and GABAergic neuronal subtypes. Scale bar represents 100 mm.
(F) Expression of Synapsin. Scale bar represents 50 mm.
(G) Raw traces of membrane potential changes to stepwise current injection of e
(H) Repetitive action potential firing was induced upon depolarizing current injec
(I) TTX-sensitive fast inward currents on depolarization.
(J) TH and Nurr1-positive DA neurons derived from BD-iNPCs. Scale bar represe
(K) HPLC for dopamine (left) and levels in multiple DA cultures (right). Scale bar r
(L) Gene set enrichment analysis for LEE_NEURAL_CREST_STEM_CELL gene li
(M) Gene set enrichment analysis for LEE_NEURAL_CREST_STEM_CELL gene l
Cneurons, which when combined with their expansion capacity,
raises the possibility of generating sufficient quantities of these
specialized cells for drug discovery, toxicity, and screening ap-
plications. We have estimated that a single round of reprogram-
ming could support the generation of as many as 100-million
sensory neurons (Figure 4L) from 50K human blood cells.
Approximately 30% to 40% of cancer patients experience the
cancer treatment complication of chemotherapy-induced pe-
ripheral neuropathy (CIPN) (NCI, 2010) through the direct impact
of the drug on nerve fibers causing nerve degeneration and axon
dieback (Boyette-Davis et al., 2011). We tested whether BD-
iNPC-derived sensory neurons showed a similar response to
chemotherapy treatment in vitro. Forty-eight hours after treat-
ment with Taxol, neurites of sensory neurons generated from hu-
man blood were quantified and showed a dose-dependent
reduction in length without concomitant loss of viability (Fig-
ure 4M). This miniaturized and automated approach illustrates
the potential utility of these converted cells as an in vitro model
of human axonopathy for drug discovery and form the basis for
future development to expand to other PNS and CNS disorders.
DISCUSSION
We provide evidence that small molecule inhibitors targeting
SMAD+GSK3 enable ectopic expression of OCT4 to directly
convert human blood progenitors into proliferative, non-tumori-
genic neural precursors with unique multipotent developmental
properties that includes generation of both DA and sensory neu-
rons. Unlike skin fibroblasts with hallmarks of neural lineages,
purified CD34+CD45+ blood is devoid of ectoderm derived cells,
and as such, BD-iNPCs represent evidence for epigenetic con-
version of cell fate state from one developmentally distinct cell
type to another (Rieske et al., 2005). Within the context of fibro-
blast reprogramming, expression of OCT4 and the addition of
basal neural progenitor culture conditions are sufficient to sup-
port conversion toward iNPCs (Mitchell et al., 2014b), whereas
generation of BD-iNPCs shown here is highly dependent on
the usage of SMAD+GSK-3 inhibition. As inhibition of these
pathways has already been established as ameans of specifying
neural identity within cells undergoing cell fate changes (Cham-
bers et al., 2009; Li et al., 2011), we hypothesize OCT4-induced
plasticity within hematopoietic cells similarly responds to these
cues in order to support direct conversion toward the neural line-
age. Previous attempts to convert human hematopoietic tissue
toward the neural lineage were restricted to the use of neonatal
cord blood-derived MSCs (Yu et al., 2015) or have resulted in
the production of neuronal restricted progenitors with limitedd O4-positive oligodendrocytes (D). (E) Tuj1 and MAP2-positive neurons and
qual increment.
tion.
nts 100 mm.
epresents SD.
st between human fibroblasts and human blood.
ist between human blood and BD-iNPCs.
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Figure 4. Generation of Functional Nociceptive Neurons that Model Chemotherapy-Induced Neuropathy
(A) Tuj1+ neurons express BRN3A and ISL1. Scale bar represents 50 mm.
(B) Expression of NTRK1 by FACS.
(C) Transcript expression of BRN3A, ISL1, and NTRK1 during differentiation from iNPCs toward sensory neurons.
(D) Neuronal clustering (top left) and Substance P expression (low left). Scale bar represents 100 mm. (Right) RT-PCR for TAC1 (Substance P).
(E) Expression of channels, channel subunits, and receptors, specific to nociceptors.
(F) Immunocytochemistry for P2X3. Scale bar represents 100 mm.
(G and H) Calcium flux in response to 30 mM a,b-meATP treatment of day 14 sensory neurons derived from adult PB-iNPCs.
(I and J) Calcium trace (I) and distribution of cells (J) responsive to 30 mM a,b-meATP, and 1 mM capsaicin.
(K) P2X3 antagonist A-317491 significantly inhibited the calcium-response to a,b-meATP.
(L) Predicted number of nociceptors from 50K human blood progenitors.
(M) In vitro response of BD-iNPC-derived sensory neurons 48-hr post-Taxol treatment (left) and normalized dose-dependent neurite length and cell count (right).
Where applicable, scale bar represents SD.
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proliferative potential (Castan˜o et al., 2014). To the best of our
knowledge, our current study defining BD-iNPCs are the first
example of trilineage neural progenitor cells produced from
direct conversion of adult human blood.
Our report uniquely provides a practical and simple approach
for generating neural progenitor cells capable of nociceptive
neuron differentiation. Although recent work using fibroblasts
has demonstrated successful conversion toward pain sensing
neurons, these studies require a multifactor trans-differentiation
strategy that bypasses the neural progenitor state (Blanchard
et al., 2015; Wainger et al., 2015). As such, each resulting cell
is unique from one another given the heterogeneity of fibroblast
populations and complex multivector integration. BD-iNPCs
could aid in realizing goals of better understanding the periph-
eral-neuropathy component of pain associated with complex
disorders such as diabetes and chemotherapy, as well as pri-
mary pain that often precedes motor dysfunction in Parkinson’s
patients by several years (Tesfaye et al., 2013). For the purpose
of drug screening or replacement therapy, prospective isolation
or generating pure populations from single progenitor clones
will be critical to moving forward. Moreover, it will be critical
to understand how application of selectable inducible expres-
sion systems that have been widely used during mouse direct
reprogramming strategies may elucidate the required epige-
netic transformations (Wapinski et al., 2013) that take place
during human direct conversion reprogramming. Thus, further
studies are required in order to develop appropriate scale-up
protocols to allow BD-iNPCs to better serve as a personalized
neurological model system, where the conversion process
detailed here provides the foundation for patient specific
analyses.
EXPERIMENTAL PROCEDURES
Cell Culture and Derivation of iNPCs
To derive iNPCs, purified CD34+ cells from cord blood or adult mobilized pe-
ripheral blood were transduced OCT4 lentivirus in the presence of SCF, Flt-3L,
IL3, and TPO cytokines (R&D System). After 48 hr, CD34+ blood cells were
cultured on Matrigel (BD Biosciences) or irradiated MEFs with reprogramming
media and basic fibroblast growth factor (bFGF) (R&DSystem) for 5 days. Cells
were then switched to basal NPC media (DMEM/F12, 1 3 N2, 1 3 B27) (Invi-
trogen) supplemented with SB431542, LDN-193189 (Stemgent), Noggin (R&D
System), and CHIR99021 (Stemgent). After 10–14 days, neural precursors-like
colonies were manually picked and transferred to Polyornithine/Laminin
(POL)-coated culture plates for propagation with neural induction medium
supplemented with bFGF and epidermal growth factor (EGF) (R&D System).
Primary neurosphere culture was used to further enrich iNPCs. Experiments
using adult peripheral blood derived iNPCs are shown in Figures 1B, 1F, 1G,
4A, 4G, 4H, and S3.
iNPC Differentiation
For neuronal differentiation, basal media were supplemented with retinoic acid
(Sigma), forskolin (Stemgent), brain-derived neurotrophic factor (BDNF), glial
cell-derived neurotrophic factor (GDNF) (R&D System), and ascorbic acid
(Sigma). Please see Supplemental Information for specific neuronal differenti-
ation conditions. For astrocyte differentiation, media were supplemented with
5% fetal bovine serum (FBS). For oligodendrocyte differentiation, basal media
were supplementedwith SHHC25II, basic fibroblast growth factor (bFGF), and
platelet-derived growth factor (PDGF) (R&D System) for 7 days. Afterward,
PDGF and bFGF were replaced by 3,3,5-triiodothyronine (T3) hormone
(Sigma), Noggin, IGF1, NT3, and forskolin adapted from Lujan et al. (2012)
and Najm et al. (2013).CGeneration of Neuronal Subtypes from iNPC
For GABA neuron induction, we adapted Barberi et al. (2003) and Ma et al.
(2012); iNPCs were cultivated in basal medium supplemented with SHH
C25II without EGF. After 7 days, media were supplemented with VPA, NT4,
BDNF, GDNF, IGF1, and forskolin for 21 days. For DA neuron induction, we
adapted Kriks et al. (2011) and Li et al. (2011); iNPCs were cultured in basal
medium supplemented with SHH C25II and FGF8 (R&D System) without
bFGF/epidermal growth factor (EGF). After 7 days, media were supplemented
with, BDNF, GDNF, transforming growth factor-b3 (TGF-b3), ascorbic acid,
forskolin, and N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-di-
methylethyl ester (DAPT) (Sigma) for 21 days. For nociceptive sensory neu-
rons, we adapted Chambers et al. (2012), Guo et al. (2013), and Lee et al.
(2012). Briefly, iNPCs were cultured in basal medium supplemented with
SU5402, DAPT, and CHIR99021. After 4 days, media were supplemented
with BDNF, GDNF, nerve growth factor (NGF), NT3 (R&D System), ascorbic
acid, and forskolin for 7–14 days until the desired maturation stage for a given
experiment.
Statistical Methods
Unless otherwise noted, SD was used in performing a Student’s t test (two
tailed) where *p = 0.05 and **p = 0.01.
All animal procedures received the approval of the animal ethics board at
McMaster University.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.04.056.
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